{"id":730235,"date":"2023-02-09T09:28:58","date_gmt":"2023-02-09T14:28:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/"},"modified":"2023-02-09T09:28:58","modified_gmt":"2023-02-09T14:28:58","slug":"prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/","title":{"rendered":"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMINGTON, Del., Feb.  09, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v2sDu_L-iEawE49tCqQlI72R829AziqdGQ-xSpxySnEbqWsCfJJuv6hNaOK6fmGTr-mRVbgr5JWXqXe6Z_XAMmRJlewuSRwXqyMIXKO8OJo=\" rel=\"nofollow noopener\" target=\"_blank\">Prelude Therapeutics Incorporated<\/a> (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.<\/p>\n<ul type=\"disc\">\n<li>On <strong>Tuesday, February 14, at 8:40 a.m. ET<\/strong>, Kris Vaddi, Ph.D., Chief Executive Officer and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat at the <strong>SVB Securities Global Biopharma Conference<\/strong>. The live webcast is available <a href=\"https:\/\/em.meetmax.com\/ls\/click?upn=8-2F4WJjLerwnvESrYtRGEvjv2sf97dkEu-2FI5mvPNZwtYBPHtwmE9kb2207qcTtJSQzi2Vy2fqhPhgVMj1jZnxww-3D-3D1Atb_Gf2Pives6lOjEzWdXLdplIWPL-2F13XghJp7o-2BZwYDUx1WJsmw7Igr1hCDmUo-2Fs5FO2CuFNPx40aTki6Lz0xlB46ljo51MQrFmuxzO-2BuFTg9FxQ60LX-2FM3z96QJq2MsvzLj88-2FSLJrNJ5N2OVKtjdUygzEVFuL6jQJT3mhh9-2BHI6zsC0Fq8W5xLSlkBy-2FXLvS-2F3Kd-2B4crnt8k677gLSEc8TlWqjiaAJO39dexqyR5C5VpdGjLiy5C8TnyDg3AhXuxzRk4Ig40rNyXEd7gHoB0Ocu2uQHJfXs6GVP4CFCAAQzMR-2B8eM3NaABSQJjQZc2D-2BZGH8P-2Bc7fMmvIHDlHdDRLsxuWxJo1IxknBhXr5-2BUOJVc25f0TYPybXudvEIZmSpZxkKf1gBRMZHErouMZJ9K2efxQIsTQNrOBVxcMk-2BM4AOPWKAeGKJ33cmlwHPaD8-2FXlWjrasTABBCQrbOxCfudd1yYpZcNvitbeq5uKlBL3XDCErweKDr04ozwT3egpyLgrKLzcHFsLTfNVHITJdv4TlIkBOwctSO21R7D9R-2BZp-2FXA-3D\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. They will be joined by Laurent Chardonnet, Chief Financial Officer, for one-on-one meetings with investors during the conference.\n<\/li>\n<li>On <strong>Tuesday, February 21<\/strong>, two executives will speak at the <strong>2023<\/strong><strong>Wells Fargo Targeted Protein Degradation Summit<\/strong>, taking place virtually.\n<ul type=\"circle\">\n<li>Peggy Scherle, Ph.D., Chief Scientific Officer will join the 12:00 p.m. ET panel, \u201cKey Targets for Targeted Protein Degradation in Oncology and Potential Combination Strategies.\u201d\n<\/li>\n<li>Andrew Combs, Ph.D., Executive Vice President and Head of Chemistry, will speak at 1:00 p.m. ET on the panel entitled, \u201cDegradation vs. Inhibition \u2013 When does Targeted Protein Degradation make Sense and When Does it Not?\u201d<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong><br \/>\n          <br \/>About Prelude <\/strong>\n      <\/p>\n<p>Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude\u2019s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for\u00a0cancers with selectable underserved patients. Prelude\u2019s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4\/6 inhibitor, and PRT3879 a first-in-class SMARCA2\/BRM protein degrader.<\/p>\n<p>For more information, visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7LAoIdEDvlp-tTliNMkeWJG4znMOztzAPhUKsrgpJmbaDmvC_3ZBgBLSMV9ohWgABFqnQTdmLBGwC3g0UlpS8w==\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LBEDvOe7atqRf2HcTXh0vSew0Dp8xzZxzq1rPiSwN2R8kZAV3NPwmFHdtch3l2d6WfNQdbz6slTMcgEvHOnD9eFpBwUj3FyMGIK37kb5DHxpubJ1kUoe52c-Q7MZq4CiKMQdI_HuE_flcODuWEMIsg==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F_UNXAiyRqDG88F8sy_DuV1Pc0aHUt7o0x8o_wORyF98obOQRnpmi1tGG0RgfpcZfCCQ6XjQqMpK3wDKdecjfA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Lindsey Trickett<br \/>Vice President, Investor Relations<br \/>240.543.7970<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dDPmwVIVRR--Ih8RHTPiYCZwq9R1JjGBG0vsjMT0xnzdXEWa27lvtXphl_7vCH23DnTKUMI0YatRCnfIHVd0IFKWMzYCq2HhD2ilg-4torY=\" rel=\"nofollow noopener\" target=\"_blank\">ltrickett@preludetx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Helen Shik <br \/>Shik Communications <br \/>617.510.4373 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WhlXA7eN0TCUKMHEHDf7hyAryL5Y_1ACIUJqALvfsrCLJFQgvXoWCK6yfRm-sYS2Up8_FjXUvmFG-P23dN0ymdinrZiDB6YpfqjVrI2YG4_E1HPEA8KG9NI1hrsDRjr7\" rel=\"nofollow noopener\" target=\"_blank\">Helen@ShikCommunications.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODhkOTU5NjQtN2ZiNi00N2ZlLWEyNTgtYTk4OWI1NTIzYzBhLTEyMTM4NzY=\/tiny\/Prelude-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference. The live webcast is available here. They will be joined by Laurent Chardonnet, Chief Financial Officer, for one-on-one meetings with investors during the conference. On Tuesday, February 21, two executives will speak at the 2023Wells Fargo Targeted Protein Degradation Summit, taking place virtually. Peggy Scherle, Ph.D., Chief Scientific Officer will join &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-730235","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference. The live webcast is available here. They will be joined by Laurent Chardonnet, Chief Financial Officer, for one-on-one meetings with investors during the conference. On Tuesday, February 21, two executives will speak at the 2023Wells Fargo Targeted Protein Degradation Summit, taking place virtually. Peggy Scherle, Ph.D., Chief Scientific Officer will join &hellip; Continue reading &quot;Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T14:28:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences\",\"datePublished\":\"2023-02-09T14:28:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/\"},\"wordCount\":298,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/\",\"name\":\"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=\",\"datePublished\":\"2023-02-09T14:28:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences - Market Newsdesk","og_description":"WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference. The live webcast is available here. They will be joined by Laurent Chardonnet, Chief Financial Officer, for one-on-one meetings with investors during the conference. On Tuesday, February 21, two executives will speak at the 2023Wells Fargo Targeted Protein Degradation Summit, taking place virtually. Peggy Scherle, Ph.D., Chief Scientific Officer will join &hellip; Continue reading \"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-09T14:28:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences","datePublished":"2023-02-09T14:28:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/"},"wordCount":298,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/","name":"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=","datePublished":"2023-02-09T14:28:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NjI0NiM1NDAxMjMzIzIyMDIzMjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=730235"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=730235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=730235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=730235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}